Journal Article
. 2019 Feb;380(8).
doi: 10.1056/NEJMoa1814213.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Aditya Bardia 1 Ingrid A Mayer 1 Linda T Vahdat 1 Sara M Tolaney 1 Steven J Isakoff 1 Jennifer R Diamond 1 Joyce O'Shaughnessy 1 Rebecca L Moroose 1 Alessandro D Santin 1 Vandana G Abramson 1 Nikita C Shah 1 Hope S Rugo 1 David M Goldenberg 1 Ala M Sweidan 1 Robert Iannone 1 Sarah Washkowitz 1 Robert M Sharkey 1 William A Wegener 1 Kevin Kalinsky 1 
Affiliations
  • PMID: 30786188
  •     44 citations

Abstract

Background: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors.

Methods: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review.

Results: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7).

Conclusions: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).

Targeting Topoisomerase I in the Era of Precision Medicine.
Anish Thomas, Yves Pommier.
Clin Cancer Res, 2019 Jun 23; 25(22). PMID: 31227499    Free PMC article.
Highly Cited. Review.
Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer.
Maryam Nakhjavani, Jennifer E Hardingham, +2 authors, Amanda R Townsend.
J Breast Cancer, 2019 Oct 11; 22(3). PMID: 31598336    Free PMC article.
Review.
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.
Mary-Ann Bjornsti, Scott H Kaufmann.
F1000Res, 2019 Oct 12; 8. PMID: 31602296    Free PMC article.
Review.
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Burak Zeybek, Aranzazu Manzano, +18 authors, Alessandro Santin.
Sci Rep, 2020 Jan 24; 10(1). PMID: 31969666    Free PMC article.
Precision medicine for human cancers with Notch signaling dysregulation (Review).
Masuko Katoh, Masaru Katoh.
Int J Mol Med, 2020 Jan 03; 45(2). PMID: 31894255    Free PMC article.
Review.
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
En-Chi Hsu, Meghan A Rice, +19 authors, Tanya Stoyanova.
Proc Natl Acad Sci U S A, 2020 Jan 15; 117(4). PMID: 31932422    Free PMC article.
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
Salvatore Lopez, Emanuele Perrone, +21 authors, Alessandro D Santin.
Oncotarget, 2020 Feb 23; 11(5). PMID: 32082489    Free PMC article.
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Emanuele Perrone, Salvatore Lopez, +19 authors, Alessandro D Santin.
Front Oncol, 2020 Mar 03; 10. PMID: 32117765    Free PMC article.
Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.
Jay J H Park, Ellie Siden, +6 authors, Edward J Mills.
Trials, 2019 Sep 20; 20(1). PMID: 31533793    Free PMC article.
Systematic Review.
Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").
Mayer Fishman.
Transl Androl Urol, 2019 Dec 07; 8(5). PMID: 31807417    Free PMC article.
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Emanuele Perrone, Paola Manara, +19 authors, Alessandro D Santin.
Mol Oncol, 2020 Jan 01; 14(3). PMID: 31891442    Free PMC article.
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Noam Pondé, Philippe Aftimos, Martine Piccart.
Curr Treat Options Oncol, 2019 Apr 02; 20(5). PMID: 30931493
Review.
Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy.
Aadra P Bhatt, Samuel J Pellock, +16 authors, Matthew R Redinbo.
Proc Natl Acad Sci U S A, 2020 Mar 15; 117(13). PMID: 32170007    Free PMC article.
Antibody Conjugates-Recent Advances and Future Innovations.
Donmienne Leung, Jacqueline M Wurst, +3 authors, Yiqing Feng.
Antibodies (Basel), 2020 Jan 16; 9(1). PMID: 31936270    Free PMC article.
Review.
Major clinical research advances in gynecologic cancer in 2019.
Miseon Kim, Dong Hoon Suh, +6 authors, Jae Weon Kim.
J Gynecol Oncol, 2020 Apr 23; 31(3). PMID: 32319232    Free PMC article.
Review.
The Landscape of Targeted Therapies in TNBC.
Elena Vagia, Devalingam Mahalingam, Massimo Cristofanilli.
Cancers (Basel), 2020 Apr 12; 12(4). PMID: 32276534    Free PMC article.
Review.
Novel antibody-drug conjugates for triple negative breast cancer.
Aiko Nagayama, Neelima Vidula, Leif Ellisen, Aditya Bardia.
Ther Adv Med Oncol, 2020 May 20; 12. PMID: 32426047    Free PMC article.
Review.
ImmunoPET: Concept, Design, and Applications.
Weijun Wei, Zachary T Rosenkrans, +3 authors, Weibo Cai.
Chem Rev, 2020 Mar 24; 120(8). PMID: 32202104    Free PMC article.
PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression.
Teresa Gagliano, Kalpit Shah, +24 authors, Georgios Giamas.
J Clin Invest, 2020 Mar 04; 130(6). PMID: 32125284    Free PMC article.
A population-based analysis of breast cancer incidence and survival by subtype in Ontario women.
S J Seung, A N Traore, +3 authors, K J Jerzak.
Curr Oncol, 2020 Jun 04; 27(2). PMID: 32489268    Free PMC article.
Sacituzumab Govitecan: First Approval.
Yahiya Y Syed.
Drugs, 2020 Jun 13; 80(10). PMID: 32529410    Free PMC article.
Review.
Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
Andrea K Miyahira, Adam Sharp, +8 authors, Howard R Soule.
Prostate, 2019 Dec 12; 80(2). PMID: 31825540    Free PMC article.
Review.
Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
K M Fenn, K Kalinsky.
Drugs Today (Barc), 2019 Oct 05; 55(9). PMID: 31584574    Free PMC article.
Review.
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
David M Goldenberg, Robert M Sharkey.
MAbs, 2019 Jun 19; 11(6). PMID: 31208270    Free PMC article.
Review.
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.
Stefania Cocco, Michela Piezzo, +7 authors, Michelino de Laurentiis.
Int J Mol Sci, 2020 Jul 02; 21(13). PMID: 32605126    Free PMC article.
Review.
Drug Conjugates for Targeting Eph Receptors in Glioblastoma.
Puja Sharma, Callie Roberts, +3 authors, Waldemar Debinski.
Pharmaceuticals (Basel), 2020 Apr 29; 13(4). PMID: 32340173    Free PMC article.
Novel targeted therapies for metastatic breast cancer.
Khalid Jazieh, Ruth Bell, Nayan Agarwal, Jame Abraham.
Ann Transl Med, 2020 Aug 15; 8(14). PMID: 32793751    Free PMC article.
Review.
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Caroline Rousseau, David M Goldenberg, +17 authors, Françoise Kraeber-Bodéré.
J Nucl Med, 2020 Mar 15; 61(8). PMID: 32169921    Free PMC article.
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape.
Joe Mehanna, Fady Gh Haddad, +2 authors, Hampig Raphael Kourie.
Int J Womens Health, 2019 Aug 27; 11. PMID: 31447592    Free PMC article.
Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/β-Catenin signaling pathway.
Wei Xie, Yan Zhang, +6 authors, Jin Wang.
Am J Cancer Res, 2019 Sep 10; 9(8). PMID: 31497360    Free PMC article.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, +42 authors, E P Winer.
Ann Oncol, 2020 Sep 27; 31(12). PMID: 32979513    Free PMC article.
An overview of antibody-drug conjugates in oncological practice.
Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Helen Gogas, Dimitrios C Ziogas.
Ther Adv Med Oncol, 2020 Oct 23; 12. PMID: 33088347    Free PMC article.
Review.
Recent advances of antibody drug conjugates for clinical applications.
Pengxuan Zhao, Yuebao Zhang, +3 authors, Yizhou Dong.
Acta Pharm Sin B, 2020 Oct 23; 10(9). PMID: 33088681    Free PMC article.
Review.
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.
Antonio Marra, Dario Trapani, +2 authors, Giuseppe Curigliano.
NPJ Breast Cancer, 2020 Oct 23; 6. PMID: 33088912    Free PMC article.
Review.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gagan K Gupta, Amber L Collier, +13 authors, Amy H Tang.
Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32846967    Free PMC article.
Review.
An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy.
Alberto Juan, Francisco J Cimas, +3 authors, Carlos Alonso-Moreno.
Pharmaceutics, 2020 Aug 29; 12(9). PMID: 32854255    Free PMC article.
Review.
Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
Anzhelika Vorobyeva, Ekaterina Bezverkhniaia, +7 authors, Vladimir Tolmachev.
Molecules, 2020 Oct 18; 25(20). PMID: 33066684    Free PMC article.
Antibody-Drug Conjugates for Cancer Therapy.
Umbreen Hafeez, Sagun Parakh, Hui K Gan, Andrew M Scott.
Molecules, 2020 Oct 22; 25(20). PMID: 33081383    Free PMC article.
Review.
Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates.
Guolan Lu, Naoki Nishio, +6 authors, Eben L Rosenthal.
Nat Commun, 2020 Nov 11; 11(1). PMID: 33168818    Free PMC article.
Update Breast Cancer 2020 Part 3 - Early Breast Cancer.
Jens Huober, Andreas Schneeweiss, +16 authors, Achim Wöckel.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173238    Free PMC article.
Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Kwang-Ai Won, Charles Spruck.
Int J Oncol, 2020 Nov 12; 57(6). PMID: 33174058    Free PMC article.
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
Thomas M Cardillo, Diane L Rossi, +5 authors, David M Goldenberg.
Oncotarget, 2020 Nov 17; 11(43). PMID: 33196706    Free PMC article.
Verminoside from Pseudolysimachion rotundum var. subintegrum sensitizes cisplatin-resistant cancer cells and suppresses metastatic growth of human breast cancer.
Changhu Lee, Hyung Won Ryu, +4 authors, Jiyoung Park.
Sci Rep, 2020 Nov 25; 10(1). PMID: 33230126    Free PMC article.
Trop2: Jack of All Trades, Master of None.
Sára Lenárt, Peter Lenárt, +3 authors, Petr Beneš.
Cancers (Basel), 2020 Nov 15; 12(11). PMID: 33187148    Free PMC article.
Review.